<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:chebi fb="0" ids="31941">Oxaliplatin</z:chebi> is frequently used in the treatment of <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Our previous work shows that <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> induces the pro-apoptotic protein Noxa in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells </plain></SENT>
<SENT sid="2" pm="."><plain>The Bcl2-inhibitor <z:chebi fb="5" ids="53329">ABT</z:chebi>-737 is particularly effective in cells with high Noxa levels </plain></SENT>
<SENT sid="3" pm="."><plain>Therefore, we tested whether <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> and <z:chebi fb="5" ids="53329">ABT</z:chebi>-737 display synergy in killing <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: A panel of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell lines was treated with <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> and <z:chebi fb="5" ids="53329">ABT</z:chebi>-737, either alone or in combination </plain></SENT>
<SENT sid="5" pm="."><plain><z:mpath ids='MPATH_3'>Apoptosis</z:mpath> was measured by FACS analysis of sub-G1 DNA content and by Western blot analysis of caspase-3 processing </plain></SENT>
<SENT sid="6" pm="."><plain>Noxa expression was suppressed by lentiviral <z:chebi fb="40" ids="33697">RNA</z:chebi> interference </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: <z:chebi fb="0" ids="31941">Oxaliplatin</z:chebi> and <z:chebi fb="5" ids="53329">ABT</z:chebi>-737 displayed a strong synergistic apoptotic response, which was dependent on <z:mp ids='MP_0002169'>wildtype</z:mp> TP53 and oncogenic KRAS </plain></SENT>
<SENT sid="8" pm="."><plain>TP53 and KRAS were required for drug-induced Noxa expression and this was essential for <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="9" pm="."><plain><z:chebi fb="0" ids="31941">Oxaliplatin</z:chebi>, but not <z:chebi fb="5" ids="53329">ABT</z:chebi>-737, induced p53 accumulation, but both drugs stimulated Noxa expression </plain></SENT>
<SENT sid="10" pm="."><plain>Combination treatment of mice with subcutaneous <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> xenografts drastically reduced <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> volume, while single drug treatment had no effect </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSION: <z:chebi fb="5" ids="53329">ABT</z:chebi>-737 synergizes with <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> to kill <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cells </plain></SENT>
<SENT sid="12" pm="."><plain>This requires induction of Noxa by <z:mp ids='MP_0002169'>wildtype</z:mp> TP53 and oncogenic KRAS </plain></SENT>
<SENT sid="13" pm="."><plain>Future studies should explore the anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> efficacy of this drug combination in mouse models for spontaneous <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> development and in patient-derived <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell cultures and xenografts </plain></SENT>
</text></document>